Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.60 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19030542 | 0.87 | PARP1 (0.60) | PARP1PDE3BPDE3APOLBKDR | |
| SCHEMBL27126761 | 0.87 | PARP1 (0.60) | PARP1PDE3BPDE3APOLBKDR | |
| SCHEMBL5670717 | 0.81 | PARP1 (0.62) | PARP1PDE3BPDE3AHSD17B10SMYD3 | |
| SCHEMBL10130365 | 0.81 | PARP1 (0.62) | PARP1PDE3BPDE3AHSD17B10SMYD3 | |
| SCHEMBL10130302 | 0.81 | PARP1 (0.62) | PARP1PDE3BPDE3AHSD17B10SMYD3 | |
| SCHEMBL6999731 | 0.81 | PARP1 (0.80) | PARP1PDE3BPDE3AHSD17B10TP53 | |
| SCHEMBL2917545 | 0.80 | PARP1 (0.60) | PARP1PDE3BPDE3ASMYD3 | |
| SCHEMBL496236 | 0.80 | PARP1 (0.60) | PARP1PDE3BPDE3ASMYD3 | |
| SCHEMBL3641602 | 0.80 | PARP1 (0.60) | PARP1PDE3BPDE3ASMYD3KDR | |
| SCHEMBL292432 | 0.80 | PARP1 (0.60) | PARP1PDE3BPDE3ASMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| WO-2006128184-A2 | PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS-PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| EP-0980362-B1 | SUBSTITUTED HETEROCYCLES AND THEIR USE IN MEDICAMENTS | SCHERING AG (DE) | 2006-08-16 | — | — | EP | disclosed |
| US-6191127-B1 | ANTIINFLAMMATORY AGENTS, AUTOIMMUNE DISEASES, CARDIOVASCULAR DISORDERS, NERVOUS SYSTEM DISORDERS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-02-20 | — | — | US | disclosed |
| EP-0980362-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE IN MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-02-23 | — | — | EP | disclosed |
| WO-1998050372-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE IN MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-11-12 | — | — | WO | disclosed |
| US-3935203-A | ANALGESICS, ANTI-OEDEMATOUS | CERPHA (FR) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | PARP1 326/4885PDE3B 605/4885PDE3A 767/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | PARP1 326/4885PDE3B 605/4885PDE3A 767/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | PARP1 326/4885PDE3B 605/4885PDE3A 767/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | PARP1 326/4885PDE3B 605/4885PDE3A 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.